key: cord-0736695-pbuaqg48
authors: Gurevich, Michael; Zilkha-Falb, Rina; Sonis, Polina; Magalashvili, David; Menascu, Shay; Flechter, Shlomo; Dolev, Mark; Mandel, Mathilda; Achiron, Anat
title: SARS-COV-2 Memory B and T Cells Profile in Mild COVID-19 Convalescents subjects
date: 2021-12-08
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.12.309
sha: ddeb2c9f32c4c3ec7d121da21684f1313aedcf51
doc_id: 736695
cord_uid: pbuaqg48

Objectives . Antiviral adaptive immunity involves memory B-(MBC) and T-cells (MTC), however their dynamics in SARS-CoV-2 convalescents warrant further investigation. Methods . In the cross-sectional and longitudinal study, we evaluated blood-derived MBC- and MTC-responses in 68 anti-spike IgG-positive mild-COVID-19 convalescents at visit 1 between 1-7 months (median 4.1 months) after disease onset. SARS-CoV-2 anti-spike IgG was performed by ELISA, MBC by SARS-COV-2 specific receptor binding domain (RBD) Elispot and Interferon gamma (IFNg), interleukin 2 (IL2) and IFNg+IL2 secreting MTC by IFNg and IL2 SARS-CoV-2 FluoroSpot. For 24 patients sampled at first visit, the IgG, MBC and MTC analysis were also performed 3 months later at second visit. Results . Seventy two percent were both MBC- and MTC-positive, 18 % - MBC-positive and MTC-negative, and 10% - MTC-positive and MBC-negative. The peak of MBC-response level was detected at 3 months after COVID-19 onset and persisted up to 7 months post infection. A significant MTC-levels were detected one month after onset in response to S1, S2_N and SNMO peptide pools. The frequency and magnitude of MTC response to SNMO was higher than to S1 and S2_N. Longitudinal analysis demonstrated that even when specific humoral immunity declined, the cellular immunity persisted. Conclusion . Our findings demonstrate durability of adaptive cellular immunity at least for 7-months after SARS-CoV-2 infection that suggest long-lasting protection.

Abbreviation: SARS-COV-2 -Severe acute respiratory syndrome coronavirus 2, MBC -memory B Cells, MTCmemory T cells, COVID-19 -Coronavirus disease 2019, IgGimmunoglobulin G, RBDreceptor binding domain, SFUspot forming units, IFNginterferon gamma, IL2interleukin 2.

The progressive decline of anti-SARS-COV-2 antibody level in convalescent subjects after primary infection (Achiron et al. 2021 ; Hartley et al. 2020 ; Rodda et al. 2021 ; Sakharkar et al. 2021) , raises the possibility for SARS-COV-2 re-infection, once the humoral immunity is diminished. This draws attention to longstanding immunity against SARS-COV-2 involving memory B and memory T cells (MBC and MTC, respectively) . The presence of specific anti-SARS-COV-2 MBC and MTC was demonstrated in convalescent patients (Forthal 2021 ; Hartley et al. 2020 ; Peng et al. 2006 ; Peng et al. 2020 ; Rodda et al. 2021 ; Schwarzkopf et al. 2021 ; Sekine et al. 2020 ; Sherina et al. 2021 ; Thieme et al. 2020) .

Several recent studies have shown that SARS-COV-2 specific IgG persist and accompanied by simultaneously increased proportions of MBC and MTC up to 8-9 months after disease onset Sandberg et al. 2021 ; Sherina et al. 2021) while other have shown a decline in SARS-COV-2 IgG levels accompanied by persistence and even increase of MBC at least for 5 months after disease onset (Hartley et al. 2020 ; Rodda et al. 2021 ; Sakharkar et al. 2021 ).

In view of reported decline of IgG levels in COVID-19 convalescence the long-lasting adaptive immunity is most relevant for re-call immune response in case of re-infections. The recently reported, low frequency of SARS-COV-2 re-infection in seronegative subjects (Leidi et al. 2021 ; Murchu et al. 2021 ) raises the possibility of anti-SARS-COV-2 defense by re-call adaptive immunity. Therefore, we profiled SARS-COV-2 MBC and MTC response and MTC repertoire in anti-spike IgG positive mild COVID-19 convalescent subjects. Particularly, we assessed the MBC and MTC response in convalescents with declined IgG level.

SARS-COV-2 convalescents were included in the study according to the following criteria: a) positive RT-PCR SARS-CoV-2 RNA nasopharyngeal swab; b) positive anti-SARS-COV-2 IgG test. None of the patients required hospitalization and the disease severity was mild presented with at least one of the symptoms: fatigue, weakness, muscles pain, cough and fever. As a negative control group, we included healthy subjects who had no history of SARS-COV-2 symptoms, no household contact with infected patients and were seronegative to anti-spike SARS-COV-2. Blood samples for immune assessments were obtained from all participants (N=84), including 68 convalescents and 16 healthy subjects. MBC response was performed in all 68 convalescents and 41 subjects were evaluated for MTC at first visit. For longitudinal study, 24 patients characterized by reduced anti-spike IgG test 3 months later (second visit), were repeatedly analyzed for MBC and MTC test.

This study was approved by Sheba Institutional Review Board SMC-750320 and informed consent was obtained from all participants.

Immunoassay for the detection of SARS-CoV-2 IgG antibodies in blood samples was performed using Euroimmun (EI, Lubeck, Germany) anti-SARS-CoV-2 IgG quantitative ELISA kit based on a recombinant S1 subunit of the SARS-CoV-2 spike protein. Tests were performed in accordance with manufacturer instructions using AGILITY® automated ELISA analyzer (DYNEX Technologies Inc., Chantilly, VA). Optical density (OD) was detected at 450 nm, and a ratio of the reading of each sample to the reading of the calibrator, included in the kit, was calculated for each sample (denoted as IgG Score below). IgG Score values higher than 1.0 were considered positive.

Analysis of SARS-CoV-2 specific MBC was performed by the FluoroSpot assay for the detection of RBD-specific MBCderived IgG-secreting cells, following polyclonal B cell stimulation. We used human IgG SARS-CoV-2 receptor-binding domain (RBD) specific ELISpotPLUS kit (ALP kit, Mabtech, Sweden) according to manufacturer instructions. Briefly, peripheral blood mononuclear cells (PBMC) were incubated (250,000 cells/well) on anti-IgG FluoroSpot plate after stimulation with a mixture of R848 (1µg/ml) and IL2 (10ng/ml) (B-Cell stimpack, Mabtech, Sweden). The number of SARS-COV-2 specific IgG-secreting B-cells was measured as Spot Forming Units (SFU) using Mabtech IRIS TM reader. The results were expressed as the number SFU per 250,000 seeded cells after subtracting the background of unstimulated cells. The positive cut-off value was set above the 90% confidence interval in healthy subjects (HS).

The interferon gamma (IFNg), interleukin 2 (IL2) and IFNg+IL2 secreting MTC were detected using Human IFNg and IL2 SARS-CoV-2 FluoroSpot PLUS kits according to the manufacture's protocol (Mabtech AB, Sweden). The pre-coated plates with monoclonal anti-IFNg/IL2 were incubated overnight in RPMI-1640 medium containing 10% FCS supplemented with SARS-CoV-2 peptide pools, or non-specific anti-CD3 stimuli (0.1 µg/ml) in presence of anti-CD28 (0.1 µg/ml) and 300 000 cells per well in a humidified incubator (5% CO2, 37 o C).

The SARS-CoV-2 S1 scanning pool contains 166 peptides from the human SARS-CoV-2 virus (#3629-1, Mabtech AB). The peptides are 15-mers overlapping with 11 amino acids, covering the S1 domain of the S protein (amino acid 13-685). The S1

pool is supplied as S1_1 (1-83) and S1_2 (84-166) peptides. The SARS-CoV-2 SNMO defined peptide pool contains 47 synthetic peptides binding to human HLA, derived from the S, N, M ORF3a and ORF7a proteins (#3622-1, Mabtech AB) (Peng et al. 2020) . The SARS-CoV-2 S2_N defined peptide pool contains 41 synthetic peptides binding to human HLA derived from the S and N proteins of the SARS-CoV-2 virus (#3620-1, Mabtech AB) (Ahmed et al. 2020) .

Results of ELISpot and Fluorospot assays were evaluated using an IRIS-reader and analyzed by IRIS software version 1.1.9 (Mabtech AB). Peptide-pools specific-responses were quantified by measuring IFNg, IL2 or IFN+IL2 producing MTC. The measurements of at least 5.0 SFU, that were at least 2-fold higher than the SFU background in culture media were considered positive. The background SFU were subtracted from measurements and expressed as SFU/250,000 cells. To assess, the overall IFNg, IL2 or IFNg+IL2 producing MTC response as a positive or negative we have taking to consideration the subjects with at least one positive response for either IFNg, IL2 or IFNg+IL2 to at least one of SARS-COV-2 peptide pools. To assess continued overall MTC response in relation to one of analyzed cytokines we have summarized the positive SFU of specific cytokine secreting MTC in response to S1, S2_N and SNMO peptides as previously described (Sherina et al. 2021 ). The positive cut-off value was set above 90% confidence interval of number specific MTC in the healthy controls.

All continuous characteristics are described as the mean±(SD) non-continuous characteristics are described as medians with 25-75% interquartile range (IQR). Differences were determined by the Mann-Whitney U test, Fisher's exact test and Chi Square test, correlation assessed by Spearman (Rank) test, pvalue < 0.05 indicated significance.

Sixty-eight anti-Spike-IgG positive COVID-19 convalescents, 25 females, mean+SD age 39.3±13.2 years with median time from disease onset (TFO) at first visit 4.1, IQR 2.6-6.1 months, were included in the study. All were subjected for MBC analysis and 35 patients (age 42.0±12.8 years,11 females) were subjected for MTC. From this cohort 24 subjects (age 34.6±18.3 years, 8 females), were tested twice: at first visit with median 4.1 IQR months TFO and 3 months later at second visit with median 7.1, IQR 6.7-8.3 months TFO. The study design is presented in Figure 1 and the representative images of MTC and MBC detection are presented in Figure 2 .

At first visit, all convalescents were positive for anti-spike IgG with average titer of 4.33±2.89 (OD ratio), 72 % were positive for both MBC and MTC, 18 % were positive for MBC and negative for MTC and 10 % were positive for MTC and negative for MBC.

The level of SARS-COV-2 specific anti-spike IgG in HS is negligible (median 0), while in convalescents the level of IgG was significantly higher at 1 month TFO (median 2.3, p<0.05) and remained persistent and significantly higher than in HS for the next six months. (Supplementary Figure 1) . Similarly, anti-RBD specific MBC gradually increased, and reached significantly higher level as compared with HS at 3 months (median 24.8 and 6.8 respectively, p<0.02) and remained significantly higher than in HS at 5 and 7 months, while no differences were observed between different time points. ( Figure 3A ). While the MBC significantly elevated at 3 month TFO, MTC was characterized by earlier response. The IFNg, IL2 and poly-functional IFNg+IL2 secreting MTC were significantly increased already at one month TFO and persisted up to 7-months (p<0.005, IFNg-and IL2-secreting MTC were correlated as well (r=0.48, p=0.001, Figure 4D ). No significant correlations were observed between IgG and MTC and between MBC and MTC with TFO.

To determine if MTC is generated and sustained in COVID-19 convalescents, we simultaneously measured the number of IFNg, IL2 and IFNg+IL2-secreting MTC in response to stimulation with SARS-CoV-2 S1, S2_N and SNMO peptide pools.

The significantly highest frequencies of individuals with positive IFNg, IL2 and IFNg+IL2 secreting MTC were observed in response to SNMO pool (82.9%, 57.5% and 72.3%, respectively) as compared to S1 (56.6%, 34.1% and 43.0% respectively, p<0.0001) and S2_N (31.7%, 7.3% and 17.5% respectively, p<0.0001) (Supplementary Table 1 ). In addition, the SFU levels of at least IFNg producing MTC in response to SNMO were significantly higher than in response to S1 or S2_N (Supplementary   Table 2) As demonstrated by SFU number, stimulation with SNMO pool was characterized by more earlier immediate and persistent response of IFNg, IL2 and IFNg+IL2 secreting MTC then stimulation with S1 and S2_N peptides. After stimulation with SNMO IFNg, IL2 and IFNg+IL2 secreting MTC were significantly increased already after 1 month TFO and still elevated up to 7 months follow up (P<0.05) (Figure. 5) . The response to S1 peptide was delayed and significantly different from these of HS at 5 and 7 months in either cytokine producing MTC (Supplementary Figure 2) . The response to S2_N peptide pool was minor and observed in IFNg-secreting MTC at 5 months TFO (Supplementary Figure 3) . No statistical differences were observed in level of IFNg, IL2 and IFNg+IL2 secreting MTC in convalescents at different time points

As we previously demonstrated, the level of SARS-COV-2 anti-spike IgG decreased by 50% but still prevailed over period of 9 months (Achiron et al. 2021) . To better understand the longitudinal memory cells response, we analyzed the dynamics of IgG, MBC and MTC from the same patient in two repeated visits. Specifically, cellular memory was characterized in 24 convalescents that were anti-spike IgG positive at first visit and had declined IgG level at the second visit. Six of 24 convalescent patients with positive IgG at first time point (median 1.22 IQR 1.14-1.58) switched to IgG-negative (median 0.66 IQR 0.40-0.96, p=0.008) at second time points (Figure 6 A) . All patients in this subgroup characterized by increasing or no change in number of MBC (median 23.5 IQR 0-28.9 and 28.1 IQR 19.0-56.3 respectively, p=0.002) (Figure 6 B) . However, the overall IFNg-secreting, IL2-secreting and IFNg+IL2-secreting MTC remained persistent at both time points respectively, p>0 .05, Supplementary Figure 4 A 

Prevention from re-infection involves cellular memory components programmed to rapidly response to antigen encounter generating memory B and T cells (Cromer et al. 2021 ; Forthal 2021 ; Mazzoni et al. 2021 ; Turner et al. 2021 ; Ueffing et al. 2020 ). Our study demonstrates the simultaneous presence of robust SARS-COV-2 anti-spike antibodies, and durable memory B and T cell responses specific for SARS-COV-2 peptides in subjects recovered from COVID-19 up to 7-months postinfection. We demonstrated that the levels of MBC and MTC increased shortly after onset. Notably, the MTC response preceded RBD-specific MBC, as was reported previously ). The MTC response was characterized by IFNg, IL2 and IFNg+IL2 secreting MTC in response to S1, S2_N, and SNMO peptide pools.

The observed dynamics of humoral and adaptive immune response well corroborated with previous publications reporting that anti-spike IgG remained stable up to 6 months after diagnosis Gaebler et al. 2021 ; Hartley et al. 2020 ; Sherina et al. 2021 ). The observed humoral response detected against the spike and the recall memory B cell response against RBD support the long-lasting protection from SARS-COV-2 infection. Moreover, our results suggest that even when SARS -COV-2 antibody level switches to seronegative, the presence of MBC and MTC potentially provides defense in case of reinfection. Numerous studies describe around 1% of re-infections (Leidi et al. 2021 ; Murchu et al. 2021) . This low frequency re-infection cases could be probably explained by the presence and involvement of adaptive immunity components i.e. memory B and T cells. This notion is further strengthened by recent study (McMahan et al. 2021) showing that relatively low antibody titers are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune responses may contribute to protection if antibody responses are suboptimal.

The findings of IFNg-secreting effector MTC suggest an immediate, but not sustained protection at pathogen sites of entry, whereas central MTC characterized by IL2 or IFNg+IL2 secretion suggests a sustained long-lasting response by proliferating in the secondary lymphoid organs and producing a supply of new effectors (Forthal 2021) .

IL2 is a growth factor for cellular expansion of specific T cells and the generation of effector and memory T cells (Abbas et al. 2018 ) as was previously detected upon in-vitro stimulation of PBMCs from both acute and convalescent COVID-19 patients (Braun et al. 2020 ; Grifoni et al. 2020 ; Peng et al. 2020 ; Sekine et al. 2020 ; Thieme et al. 2020 ; Weiskopf et al. 2020) .

Intracellular staining revealed that both CD8+T and CD4+ T cells are sources of this cytokine but CD4+T cells appear to be the main producers (Braun et al. 2020 ; Grifoni et al. 2020 ; Peng et al. 2020 ; Sekine et al. 2020) . Based on the production of IFNg and IL2, SARS-COV-2-specific CD4 + T cells could be divided into three distinct populations: single IFNg-secreting cells, double IFNg+IL2-secreting cells and single IL2-secreting cells ). This classification further demonstrates the heterogeneity of MTC and also indicated that distinct subpopulations of memory CD4+ T cells have different capacities to develop into short/effector IFNg-secreting and long-lived/central IL2-secreting and IFNg+IL2-secreting MTC .

As expected, our results demonstrated T cell response for all SARS-COV-2 peptide pools. Particularly in convalescents, SNMO peptide pools elicited the strongest memory T cell responses, that likely reflect the exposure to whole viral particle components including spike (S), nucleoprotein (N), membrane protein (M), and ORF (ORF)-3a and ORF-7a (Peng et al. 2020) . Although it seems evident that the SNMO pool will create higher responses when compared to S1 or S2, previous studies have shown that S1 pool had significant higher reactivity in COVID-19 recovered individuals than in healthy controls and that SFU fold changes for S1 pool are higher than these for SNMO (Long et al. 2021 ) and significant more poly-functional T cell responding to the S1 peptide pool as compared to the N peptide pool in convalescents (Sandberg et al. 2021 ) therefore the finding of higher SNMO SFU response over these of S1 pool is not easily straightforward.

The S1 proposed as most specific cell binding SARS-COV-2 antigen and S2_N pools yielded modest responses. In accordance, we expect that the response of vaccinated subjects (with the mRNA-based vaccine; Pfizer BNT162b2) will be elicited dominantly to spike protein peptide pool.

In view of recently developed anti-SARS-COV-2 vaccines and reported decline in antibody titers in vaccinated subjects (Bates et al. 2021 ; Sariol et al. 2021 ) and convalescent patients (Gaebler et al. 2021) it was interesting to follow MBC and MTC levels in patients switching to seronegative status. The critical question in patients with the decline of circulating antibodies is whether the other elements of immunological resistance against SARS-COV-2 infection are still exist.

Our results show that robust T and B cell response in such patients not only persistent but even increase, similar to previous study in which disappearing of SARS-COV-2-specific IgG was associated with durable memory T cells response as compared to convalescents who remained IgG-positive (Schwarzkopf et al. 2021 ). Our results are in line with previous publications related to MERS and SARS-CoV-1 infections in which memory T cells response was observed when antibody response wane (Abayasingam et al. 2021 ; Alshukairi et al. 2016 ; Channappanavar et al. 2014 ; Zhao et al. 2017) . Similarly, Sandberg et al., (2021) and Sherina at al., (2020) (Sandberg et al. 2021 ; Sherina et al. 2021) showed robust MBC and MTC response in patients with gradually decreased antibody level following 8-9 months after SARS-COV-2 onset ).

This suggest that although titers of antibody waning, an effective immune response to future infections could be developed by cellular memory components. Considering high mutation rate of SARS-COV-2 virus and potential immune escape and that different spike mutations impaired SARS-CoV-2 antigenicity (Harvey et al., 2021) , it remains open question whether the original memory cells will cross-react with SARS-COV-2 variants. Although the existing evidence that the spike amino acid changes affect antibody neutralization (Harvey et al., 2021) and some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, yet, S-specific CD4 + T cell activation is not affected by the mutations at least in the B.1.1.7 and B.1.351 variants (Geers et al. 2021) . SARS-CoV-2 variants analyzed by Tarke et al., 2021 did not significantly disrupt the total SARS-CoV-2 T cell reactivity; however, the decreases observed in responses, highlight the importance for active monitoring of T cell reactivity in the context of SARS-CoV-2 evolution (Tarke et al. 2021 ).

1. The durable immune humoral and adaptive response are observed in SARS-COV-2 convalescent patients with mild symptoms for up to 7 months, suggesting the longevity of humoral and adaptive immunity in convalescent individuals.

2. In convalescent patients the T cell response to S1, S2_N, and SNMO peptides pools is characterized by presenting IFNg and IL2 -secreting T Cells and poly-functional IFNg+IL2-secreting T cells.

3. In convalescent patients waning anti-spike IgG titer could be accompanied with robust MBC and IFNg producing MTC suggesting potential long-lasting recall memory response and defense from re-infection A. PBMCs (250,000 cells/well) were stimulated for 48h with S1, S2_N and SNMO of Mabtech's SARS-COV-2 peptide pools or aCD3 as a positive control. The MTC were analyzed on Mabtech IRIS TM using an IFNg or IL2 FluoroSpot assay.

B. PBMCs were stimulated with R848 and IL-2 for 96h (S). After pre-stimulation, 250,000 cells/well were incubated on an anti-IgG FluoroSpot plate for 18h. RBD specific MBC were detected using RBD-streptactin-550 conjugate . Analysis was made on the Mabtech IRIS TM . Uunstimulated cells, Sstimulated cells, MTCmemory T cells, MBCmemory B cells to S1, S2_N and SNMO, IL2 MTC -overall IL2-producing memory T cells calculated as sum of the positive SFU of IL2-secreting cells in response to S1, S2_N and SNMO, IFNg+IL2 MTC -overall IFNg+IL2 producing memory T cells calculated as sum of the positive SFU of IFNg+IL2 secreting cells in response to S1, S2_N and SNMO. * p<0.03 by Mann-Whitney U test as compared with HS. NSnon-significant as compared to HS. In A,B,C and D no significant differences in SFU levels between different time points were observed.

A. Correlation (by Spearman-Rank test) between anti-S1 spike IgG and MBC levels; B. Correlation between overall IL2 secreting MTC and MBC levels; C. Correlation between overall IFNg secreting MTC and MBC; D. Correlation between overall IFNg and IL2 secreting MTC. SFU -Spot Forming Units, MBCmemory B Cells, IFNg MTCoverall IFNg producing memory T cells calculated as sum of the positive SFU of IFNg secreting cells in response to S1, S2_N and SNMO, IL2 MTC -overall IL2 producing memory T cells calculated as sum of the positive SFU of IL2 secreting cells in response to S1, S2_N and SNMO and C no significant differences in SFU levels between different time points were observed.

A. Convalescent patients switching from positive to negative IgG level between visit 1 (black dots) and visit 2 (gray dots). B.

MBC changes in convalescent patients switching from positive to negative IgG level between visit 1 (black dots) and visit 2 (gray dots). C Patients with decreased IgG level, yet remaining IgG positive between first (black dots) and second (gray dots) visit. D. MBC changes in patients with decreased IgG level, yet remaining IgG positive. MBCmemory B Cells

Long-term persistence of RBD(+) memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection

Revisiting IL-2: Biology and therapeutic prospects

SARS-COV-2 antibody dynamics and B-cell memory response over-time in COVID-19 convalescent subjects

Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies

Antibody Response and Disease Severity in Healthcare Worker MERS Survivors

Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

T cell-mediated immune response to respiratory coronaviruses

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Adaptive immune responses to SARS-CoV-2

Evolution of antibody immunity to SARS-CoV-2

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study

Immune memory in convalescent patients with asymptomatic or mild COVID-19

Heterogeneous magnitude of immunological memory to SARS-CoV-2 in recovered individuals

Correlates of protection against SARS-CoV-2 in rhesus macaques

Quantifying the risk of SARS-CoV-2 reinfection over time

Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection

Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS-CoV-2 Spike protein after natural infection or COVID-19 vaccination

Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG

Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection

Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T¬ †cell reactivity in infected or vaccinated individuals

Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Basic principles of replication and immunology of SARS-CoV-2

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Long-lived effector/central memory Tcell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients

Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses

The authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare that they obtained an informed consent from the patients included in the article and that this report does not contain any personal information that could lead to their identification.

The authors have no conflicts of interest to report.